Literature DB >> 3715945

Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.

J B Bederson, L H Pitts, M Tsuji, M C Nishimura, R L Davis, H Bartkowski.   

Abstract

We have examined the incidence and size of infarction after occlusion of different portions of the rat middle cerebral artery (MCA) in order to define the reliability and predictability of this model of brain ischemia. We developed a neurologic examination and have correlated changes in neurologic status with the size and location of areas of infarction. The MCA was surgically occluded at different sites in six groups of normal rats. After 24 hr, rats were evaluated for the extent of neurologic deficits and graded as having severe, moderate, or no deficit using a new examination developed for this model. After rats were sacrificed the incidence of infarction was determined at histologic examination. In a subset of rats, the size of the area of infarction was measured as a percent of the area of a standard coronal section. Focal (1-2 mm) occlusion of the MCA at its origin, at the olfactory tract, or lateral to the inferior cerebral vein produced infarction in 13%, 67%, and 0% of rats, respectively (N = 38) and produced variable neurologic deficits. However, more extensive (3 or 6 mm) occlusion of the MCA beginning proximal to the olfactory tract--thus isolating lenticulostriate end-arteries from the proximal and distal supply--produced infarctions of uniform size, location, and with severe neurologic deficit (Grade 2) in 100% of rats (N = 17). Neurologic deficit correlated significantly with the size of the infarcted area (Grade 2, N = 17, 28 +/- 5% infarction; Grade 1, N = 5, 19 +/- 5%; Grade 0, N = 3, 10 +/- 2%; p less than 0.05). We have characterized precise anatomical sites of the MCA that when surgically occluded reliably produce uniform cerebral infarction in rats, and have developed a neurologic grading system that can be used to evaluate the effects of cerebral ischemia rapidly and accurately. The model will be useful for experimental assessment of new therapies for irreversible cerebral ischemia.

Entities:  

Mesh:

Year:  1986        PMID: 3715945     DOI: 10.1161/01.str.17.3.472

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  678 in total

1.  Piperine suppresses cerebral ischemia-reperfusion-induced inflammation through the repression of COX-2, NOS-2, and NF-κB in middle cerebral artery occlusion rat model.

Authors:  Kumar Vaibhav; Pallavi Shrivastava; Hayate Javed; Andleeb Khan; Md Ejaz Ahmed; Rizwana Tabassum; Mohd Moshahid Khan; Gulrana Khuwaja; Farah Islam; M Saeed Siddiqui; Mohammed M Safhi; Fakhrul Islam
Journal:  Mol Cell Biochem       Date:  2012-06-06       Impact factor: 3.396

2.  Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study.

Authors:  Rick M Dijkhuizen; Aneesh B Singhal; Joseph B Mandeville; Ona Wu; Elkan F Halpern; Seth P Finklestein; Bruce R Rosen; Eng H Lo
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

3.  The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats.

Authors:  Sheng Peng; Zhongshen Kuang; Yan Zhang; Hang Xu; Qinghong Cheng
Journal:  Mol Biol Rep       Date:  2010-05-16       Impact factor: 2.316

4.  Mild sensory stimulation reestablishes cortical function during the acute phase of ischemia.

Authors:  Christopher C Lay; Melissa F Davis; Cynthia H Chen-Bee; Ron D Frostig
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

5.  A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.

Authors:  Weihua Guan; Yumei Zhao; Chao Xu
Journal:  Transl Stroke Res       Date:  2010-11-16       Impact factor: 6.829

6.  ICAM-1null C57BL/6 Mice Are Not Protected from Experimental Ischemic Stroke.

Authors:  Gaby U Enzmann; Sofia Pavlidou; Markus Vaas; Jan Klohs; Britta Engelhardt
Journal:  Transl Stroke Res       Date:  2018-02-04       Impact factor: 6.829

7.  CD151 Alleviates Early Blood-Brain Barrier Dysfunction After Experimental Focal Brain Ischemia in Rats.

Authors:  Wendeng Xu; Ceshu Gao; Jian Wu
Journal:  Cell Mol Neurobiol       Date:  2020-04-13       Impact factor: 5.046

8.  Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death.

Authors:  Thiruma V Arumugam; Sung-Chun Tang; Justin D Lathia; Aiwu Cheng; Mohamed R Mughal; Srinivasulu Chigurupati; Tim Magnus; Sic L Chan; Dong-Gyu Jo; Xin Ouyang; David P Fairlie; Daniel N Granger; Alexander Vortmeyer; Milan Basta; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

9.  Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and neuroprotection.

Authors:  Jed A Hartings; Michael L Rolli; X-C May Lu; Frank C Tortella
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

10.  U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats.

Authors:  Hilda Ahnstedt; Maryam Mostajeran; Frank W Blixt; Karin Warfvinge; Saema Ansar; Diana N Krause; Lars Edvinsson
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.